In summary, the results of our study evidencing CORM-A1-mediated amelioration of mitochondrial function in steatotic liver via Nrf2, is the first to directly suggest the therapeutic potential of CORM-A1 for the clinical management of NASH and fatty liver. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatohepatitis.